Colony Bankcorp, Inc. operates as the holding firm for Colony Bank that provides banking services and products to commercial and consumer customers. The company has market cap of $116.04 million. It offers various deposit products, including demand, savings, and time deposits. It has a 15.8 P/E ratio. The firm also offers loans to small and medium-sized businesses; residential and commercial construction, and land development loans; commercial real estate loans; commercial loans; agri-business and production loans; residential mortgage loans; home equity loans; and consumer loans.
Blume Capital Management Inc decreased Teva Pharmaceutical (TEVA) stake by 99.5% reported in 2017Q3 SEC filing. Blume Capital Management Inc sold 118,980 shares as Teva Pharmaceutical (TEVA)’s stock declined 15.11%. The Blume Capital Management Inc holds 600 shares with $11,000 value, down from 119,580 last quarter. Teva Pharmaceutical now has $20.79B valuation. The stock decreased 2.17% or $0.4538 during the last trading session, reaching $20.4462. About 9.04 million shares traded. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has declined 41.70% since February 20, 2017 and is downtrending. It has underperformed by 58.40% the S&P500.
Among 35 analysts covering Teva Pharma (NYSE:TEVA), 9 have Buy rating, 8 Sell and 18 Hold. Therefore 26% are positive. Teva Pharma had 146 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Reduce” rating given on Tuesday, November 7 by HSBC. OTR Global initiated the shares of TEVA in report on Thursday, September 29 with “Positive” rating. Mizuho maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating on Thursday, October 26. Mizuho has “Hold” rating and $16.0 target. The rating was maintained by Piper Jaffray with “Hold” on Friday, July 14. The firm has “Hold” rating given on Friday, November 3 by Deutsche Bank. Mizuho maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating on Friday, November 17. Mizuho has “Neutral” rating and $12 target. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Sell” rating given on Wednesday, January 24 by RBC Capital Markets. RBC Capital Markets maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) rating on Friday, December 15. RBC Capital Markets has “Sell” rating and $13.0 target. The rating was initiated by Cantor Fitzgerald on Friday, June 16 with “Neutral”. The company was downgraded on Monday, November 13 by J.P. Morgan.
The stock decreased 2.48% or $0.35 during the last trading session, reaching $13.75. About 648 shares traded. Colony Bankcorp, Inc. (CBAN) has risen 45.99% since February 20, 2017 and is uptrending. It has outperformed by 29.29% the S&P500.